Chronic graft-versus-host disease
Conditions
Interventions
Methotrexate (MTX) Group:NA
Mycophenolate mofetil (MMF) group:NA
Ruxolitinib group:NA
Sirolimus group:NA
Belumosudil mesylate group:NA
Imatinib group:NA
Rituximab group:NA
Sponsors
The Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
16 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >16 years, having undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematologic diseases with complete and regular post-transplant follow-up data (no gender restriction); 2. Self-reported active cGVHD symptoms; 3. Clinically diagnosed during follow-up as requiring systemic therapy for cGVHD (e.g., steroid-refractory/resistant after first-line treatment like glucocorticoids); 4. Voluntarily participating in this study with compliance to follow-up procedures.
Exclusion criteria
Exclusion criteria: 1. Severe organ dysfunction or failure; 2. Uncontrolled active infection 3. Severe communicable diseases; 4. Missing transplantation records or follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate (ORR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Response Rate (CRR);Organ-Specific Response Rate;Patient-Reported Outcomes (PROs);Event-Free Survival (EFS);Overall Survival (OS);Safety Profile; | — |
Countries
China
Contacts
Public ContactXi Zhang
The Second Affiliated Hospital of Army Medical University
Outcome results
None listed